PTC Therapeutics completes acquisition of Sangamo’s ST-920 Fabry gene therapy asset
PTC Therapeutics completed its acquisition of Sangamo’s ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease. A rolling BLA filing to the FDA for accelerated approval is expected to be completed in Q4 2026. ST-920, also known as isaralgagene civaparvovec, targets long-term alpha-Gal A enzyme production to re